Steel Partners, already holding a stake in InMode, has made an unsolicited cash offer of $16.75 per share to acquire the publicly traded aesthetic-device maker — a move that challenges an ongoing CEO-led buyout proposal. The bid signals confidence in InMode's core RF microneedling and body-contouring platform, which has driven consistent revenue growth and market penetration among independent medspas and DSOs.
Business & M&A
Steel Partners Bids $16.75/Share for InMode — What a Hostile Takeover Means for Device Buyers
A major shareholder's unsolicited offer upends the aesthetic-device market's M&A calculus.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
A PE-backed takeover could tighten rebate structures and financing terms for independent practices.
For practice owners, the immediate question is stability: InMode supplies the Morpheus8 RF microneedling system, Lumenis-branded body-contouring devices, and other workhorse platforms. A change in ownership—whether to Steel Partners or the competing CEO-led group—could reshape rebate structures, financing terms, and service support. Historically, PE-backed consolidations in aesthetic devices have tightened margins on equipment leases and introduced more aggressive loyalty-program requirements. InMode's Q2 2026 guidance of $95.2–$95.4M in revenue and full-year guidance of $365–$375M suggests the business remains attractive to acquirers.
Source: original report ↗
Frequently asked questions
What does Steel Partners' bid for InMode mean for Morpheus8 pricing and availability?
A change in ownership could affect rebate structures, financing terms, and service support for InMode devices like Morpheus8. Historically, PE-backed acquisitions in aesthetic devices have tightened margins on equipment leases and introduced more aggressive loyalty-program requirements, so medspas should monitor contract terms closely during any transition.
Will InMode's hostile takeover affect my device service and support?
Ownership changes often reshape how vendors handle service support and customer relationships. While InMode's current revenue guidance ($365–$375M full-year) suggests the business remains stable, medspas should document current service agreements and clarify support commitments with InMode before any deal closes to avoid disruption.
What is Steel Partners' $16.75 offer compared to InMode's current value?
Steel Partners' unsolicited bid of $16.75 per share competes with an ongoing CEO-led buyout proposal, signaling confidence in InMode's RF microneedling and body-contouring platform. The offer reflects strong market demand for InMode's technology among independent medspas and DSOs.
Should I lock in InMode device financing before the acquisition closes?
Yes—medspas should review and potentially lock in current financing and rebate terms before ownership transitions. PE-backed consolidations typically tighten margins on equipment leases and introduce stricter loyalty programs, so securing favorable terms now protects your cost structure.
What other InMode devices could be affected by the Steel Partners bid?
Beyond Morpheus8 RF microneedling, InMode supplies Lumenis-branded body-contouring devices and other aesthetic platforms. All of these could see changes in pricing, support, and availability depending on which buyer acquires the company and how they restructure the product portfolio.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.